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Abstract
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In
addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19),
and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab
(MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/
refractory precursor B cell acute lymphoid leukemia.
Targeted therapy has been the forefront of cancer treat-
ment [1–7]. Monoclonal antibodies have played a major
role in lymphoma therapy for more than a decade [8–11].
Cancer immunotherapy is the most recent focus of clinical
development [12–17]. In addition, novel immunothera-
peutics targeting B cell receptor signaling (e.g., ibrutinib)
[2, 18], T cell receptor (e.g., CART19) [19–22], and NK
cells (e.g., AFM13) [23–25] are being developed. This
review summarized the clinical development in blinatu-
momab (MT103/MEDI-538), a first-in-class bispecific
T engager (BiTE) antibody against CD19/CD3 in patients
with relapsed/refractory precursor B cell acute lymphoid
leukemia (ALL).
Bispecific antibodies and diabody
Bispecific antibodies (bsAb) was initially developed through
hybrid-hybridoma, chemical linkage, or renaturation from
purified recombinant Fab or Fv fragment from bacterial in-
clusion bodies [11, 26, 27]. One of the major limitations of
these technologies is the difficulty in producing sufficient
amount of clinical grade bsAbs. This has made the clinical
testing of the bsAbs falling behind.
Through molecular cloning and/or phage expression
library, high affinity recombinant single-chain Fv
fragment (scFv) has been produced. This led to the de-
velopment of bivalent bispecific antibody fragments,
diabodies [11, 26, 27]. A heavy chain scFv (VH) is con-
nected with a light chain scFv (VL) by a short amino
acid linker to form a single polypeptide. The short
linker is too short to allow self association of the two
adjacent VH and VL domain. Therefore, by linking the
VH and VL of two different antibodies A and B to form
two different “cross-over” polypeptide chain VHA-VLB
and VHB-VLA, a diabody containing both antigen-binding
sites through non-covalent association is formed (Fig. 1)
[11, 26, 27]. One such functional small bispecific antibody
against EpCAM /CD3 was engineered and purified from
Chinese hamster ovary (CHO) cells [27]. This antibody
was found to be able to redirect T cells to lyse colon can-
cer cells expression EpCAM antigen. Using this approach,
clinical grade bsAbs were produced from CHO cells in
large quantity [23, 24, 28].
Structure and properties of blinatumomab
Combination chemotherapy for relapsed and/or refrac-
tory acute lymphoblastic leukemia usually leads to a
CR rate in 30–45 % of patients and overall survival of
4·7–8·6 months in first salvage treatment [29–33].
CD19 is a common B cell surface marker [34–38].
Monoclonal antibodies against CD19 have been in ac-
tive clinical development [39, 40].
In an attempt to develop novel treatment agent for re-
fractory B cell malignancies, a bsAb against CD19/CD3,
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MT103/MEDI-538 (blinatumomab), was engineered using
the diabody approach [41]. One arm of this antibody binds
CD19, while the other arm binds CD3 (Fig. 2). By redir-
ecting unstimulated primary human T cells against
CD19-positive lymphoma cells, the bispecific CD19/CD3
antibody fragment showed significant cytotoxic activity at
very low concentrations of 10 to 100 pg/mL and at effector-
to-target cell ratios as low as 2:1. This single-chain bispecific
antibody construct belongs to a new class of antibody
fragments, BiTE [42–51]. This bispecific antibody frag-
ment has a molecular weight of 54.1 kDa, approximately
one-third of the size of a traditional monoclonal antibody
(mAb). As CD19 is an attractive target, CD19 mAb has
been widely studied for therapies of lymphoma, leukemia,
and autoimmune disorders, such as anti-B4-bR, SAR3419
(huB4-DM4), and BiTE [38–40, 52]. Blinatumomab can
potentiate unstimulated T cells and induce direct cytotox-
icity against CD19+ cells [42].
Fig. 1 Gene structure and production of bispecific blinatumomab diabody. DNA sequence of the CD19 heavy chain scFv (VHA) is connected with
the CD3 light chain scFv (VLB) by a short linker (L) sequence to form a single gene encoding one peptide, VHA-VLB. By the same approach, the
DNA sequence of the CD19 light chain scFv (VLA) is connected with the CD3 heavy chain scFv (VHB) by a short linker (L) sequence to form the
second gene encoding the other peptide, VHB-VLA. The two polypeptide chains, VHA-VLB and VHB-VLA, can then heterodimerize non-covalently to
form a diabody containing bispecific antigen-binding sites to both CD19 and CD3
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Several properties of blinatumomab promoted its devel-
opment for immunotherapy of lymphoma and leukemia.
Because of its single-chain structure, blinatumomab can
be produced with a stable purified monomeric formula-
tion in large quantities for clinical use [23, 24, 28, 41].
Blinatumomab has been shown to increase inflammatory
cytokine production, specifically IL-2, IFN-γ, TNF-α, IL-4,
IL-6, and IL-10 [53]. Importantly, it can bridge malignant
B cells directly to CD3-positive T cells, bypassing T cell
receptor (TCR) specificity and major histocompatibility
complex (MHC) class I molecules [41, 54, 55]. The
CD19/CD3 BiTE antibody was shown to induce T-cell-
mediated depletion of primary lymphoma cells in 22 out
of 25 cases. This effect could be observed at low effector-
to-target (E:T) ratios and in the majority of cases without
additional activation of autologous T cells by IL-2 [41, 54].
Data from animal models support a high activity of bli-
natumomab at very low doses against tumor cells in
lymphoma and leukemia models [43, 48, 55–57].
Blinatumomab in clinical development
Blinatumomab is the first-in-class BiTE antibody approved
for treatment of refractory ALL [46, 47, 58–64].
Blinatumomab was first reported in a clinical phase I
trial in 38 patients with refractory non-Hodgkin lymph-
oma [58]. Due to its short half-life and mechanism of ac-
tion, blinatumomab was given as continuous intravenous
infusion (CIV) in the study MT103-104 (NCT00274742).
The doses ranged from 5 to 60 μg/m2/day over a period of
4–8 weeks. The maximum tolerated dose (MTD) of blina-
tumomab was reported to be 60 μg/m2/day. This study
first demonstrated the efficacy of blinatumomab in B cell
malignancies. Eleven of 38 patients (28.9 %) had measur-
able response after treatment, including 4 (11 %) CR and
7 (18 %) PR. The most commonly observed adverse events
(AEs) were pyrexia, chills, and leucopenia. CNS toxicity
and cytokine release syndrome (CRS) were observed [58].
By 2011, 62 patients had been enrolled in this study
with an objective response of 18/22 (82 %) and 32-month
response duration. Blinatumomab treatment at doses
of ≥15 μg/m2/day led to depletion of tumor cells in
blood, lymph nodes, spleen, and bone marrow [58].
During or after treatment, T cell counts remained stable or
increased. Blinatumomab treatment predominantly caused
an expansion of effector memory CD8+ and CD4+ T cells
with CD45RA/CCR7 phenotype. It was also observed that
there was an early disappearance of T cells. This may be
due to a transient increase in the adhesiveness of T cells to
vessels and/or extravasation. No clinically significant cyto-
kine release syndrome was seen in any patient. There was
no autoimmune disorder observed with blinatumomab
treatment. Neutralizing antibodies against blinatumomab
was not detected in these patients [58].
A single-arm phase II study (MT103-206, NCT01209286)
evaluated response to blinatumomab in molecularly
relapsed/refractory precursor B cell ALL [61]. In this
study, a total of 36 patients were treated. A dose-finding
component followed by an extension cohort from 5 (week 1)
to 15 μg/m2/day on subsequent 3 weeks was included.
A 2-week treatment-free interval followed the comple-
tion of the 4-week continuous infusion of blinatumo-
mab to allow T cell recovery. CR or CRh (incomplete
hematological recovery) was observed in 25 of 36 patients
(69 %), and 22 of 25 responders (88 %) achieved a molecu-
lar remission. Response was better in patients in first
relapse than those in second or greater relapse. Median
relapse-free survival (RFS) was 7.6 months, with a 9.8-
month median overall survival (OS). With a median
follow-up of 405 days, the probability of RFS was 78 %.
The most frequent grade 3 and 4 adverse event was
lymphopenia, which was reversible. These results are
encouraging compared to the median OS of 6 months
in relapsed ALL with chemotherapy [61]. Among patients
with longer follow-up (median 33 months), 80 % response
Fig. 2 Mechanism of action for blinatumomab as the first-in-class bispecific T cell engager (BiTE). One arm of blinatumomab binds to CD3, the
other binds to CD19. This engages the unstimulated T cells which destroy the CD19+ cells
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rate with minimal residual disease (MRD) was reported
[65]. Among the 6 Philadelphia chromosome-negative
MRD responders, 4 remained in hematologic and molecu-
lar remission with no further therapy after blinatumomab.
Therefore, blinatumomab can induce long-lasting complete
remission in B-lineage ALL patients with persistent or re-
current MRD [65–67].
Subsequently, a large, multicentre, phase II trial
(MT103-211, NCT01466179) assessed blinatumomab
in 189 adult patients with relapsed or refractory B cell
ALL [62, 68]. These patients were negative for Philadelphia
chromosome and had primary-refractory disease, early first
relapse, or multiple relapses. The trial also enrolled patients
who had relapsed within 12 months after allogeneic
hematopoietic stem cell transplantation (allo-HSCT).
Patients received blinatumomab as continuous intra-
venous infusion with a flat dose of 9 μg/day at week 1
(cycle 1 only, to reduce cytokine release syndrome)
and 28 μg/day for 3 weeks. This was followed by a 2-week
treatment-free interval. Therefore, each cycle was 6 weeks,
and patients received treatment up to 5 cycles in the
study. Premedication with dexamethasone (20 mg) within
1 h of treatment initiation in each cycle and before the
dose step-up in cycle 1 was given to minimize infusion re-
actions to blinatumomab. However, high-dose (≥24 mg)
dexamethasone was only allowed for 7 days or less. The
infusion was allowed to be interrupted for AEs grade 3 or
higher and resumed after reduction of AEs to grade I or
complete resolution. The clinical response in the first 2 cy-
cles was 33 % CR (63 of 189 patients) and 10 % CRh (18
of 189 patients), with 40 % (32 of 81 patients in CR/CRh)
went on to receive allo-HSCT. Median relapse-free sur-
vival was 5∙9 months for those patients who achieved
CR/CRh, with a median OS of 6∙1 month for all 189 pa-
tients [68]. Among the 73 responders with available
data on MRD, 80 % of patients achieved MRD negativity
[69]. The relative odds ratio by Mantel-Byar analysis
for survival benefit of achieving remission was 0.13
(p < 0∙0001). Responses in patients older than 65 years
and in those who received previous allo-HSCT were
noted. These two patient groups for whom treatment
options are very limited due to substantial toxicity as-
sociated with currently available polychemotherapies.
Common AEs associated with blinatumomab such as
febrile neutropenia, neutropenia, and anemia were con-
sistent with those previously reported. CRS in grade 3 oc-
curred in 3 (2 %) patients [68, 70]. Neurologic events,
including tremors, seizure, and mental status change, were
seen in 98 (52 %) patients, mostly in grade 1 or 2, with 20
(11 %) in grade 3 and 4 (2 %) in grade 4. In these patients
with high-risk features, 40 % of them went on to allo-
HSCT (17 % for those with prior transplantation, 52 %
with no prior transplantation). There were patients who
had response to blinatumomab but did not receive allo-
HSCT because they were ≥65 or had prior HSCT that
precluded them from allo-HSCT [71].
In a separate confirmatory trial, BLAST trial, 116 adult
patients (median age 45, range 18–76) with MRD+ pre-B
ALL were treated with continuous IV infusion of blinatu-
momab at 15 μg/m2/day in a similar schedule (4-week
treatment, 2-week rest) as described above [72]. The MRD
negative response rate was 78 % (95 % CI, 69–85 %) after
1 cycle of treatment. The results appeared to be consistent
with those from previous studies [65, 68].
Blinatumomab was also studied in pediatric patients
with relapsed/refractory pre-B ALL in a phase I/II clinical
trial [73]. Patients received blinatumomab for 4 weeks by
continuous IV infusion followed by a 2-week treatment-
free period (for up to 5 cycles). Escalating dosing levels of
5, 15, and 30 μg/m2/day and stepwise dosing of 5–15 or
15–30 μg/m2/day were evaluated. In the phase I portion,
41 patients were treated. A total of 13 (32 %) patients
achieved CR with 10 (77 %) achieving MRD negativity.
Of these 13 patients, 9 (69 %) went on to have HSCT.
The adverse events as well as pharmacokinetic data,
including steady-state concentration, clearance, and
half-life were similar to those from adult patients with
relapsed/refractory BCP-ALL who received body sur-
face area-based dosing. The MTD was 15 μg/m2/day in
the pediatric patients. Stepwise dosing was useful in
reducing CRS. The 5 (week 1) to 15 μg/m2/day (week 2
to 4) step-wise dosing was therefore used for phase II
portion of the study. At the time of last update, 39 pa-
tients were treated at this dose (median age 9, range
2–18) [74]. Blinatumomab showed promising antileuke-
mia activity in this group of high-risk pediatric relapsed/
refractory B cell precursor ALL patients. Among patients
who had remission after the first 2 cycles of blinatu-
momab single-agent therapy, half went on to receive
allo-HSCT. Therefore, blinatumomab may create a win-
dow for allo-HSCT for those patients who are resistant to
salvage chemotherapy [73–75].
Conclusion and future directions
Blinatumomab represents the first-in-class BiTE anti-
body in clinical use and provides a novel therapeutic
option for patients with relapsed/refractory B cell ALL
[43, 58, 64, 67, 76]. The pharmacodynamics and immu-
nophenotype data are still being collected [67]. One obvi-
ous disadvantage of this BiTE antibody is the requirement
for continuous IV infusion because of the small molecular
weight and rapid clearance from circulation. Newer tetra-
valent bispecific antibodies, AFM11 and AFM13, can be
given as weekly or twice weekly [23, 24, 28]. T cells with
CD19/CD3 chimeric antigen receptors (CAR-T) have
been shown to induce high remission rate (90 % CR in
refractory ALL), and can expand 1000 times in vivo
[77–80]. The rate of CRS associated with CAR-T therapy
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(27 % severe) was much higher than that of blinatumomab
(2 %). CAR-T was shown to penetrate blood-brain barrier
[78]. It is not known whether blinatumomab has similar
property. It remains unclear what is the optimal treatment
duration and schedule of blinatumomab for patients
who cannot receive allo-HSCT. The role of consolidation
or maintenance for blinatumomab also remains an area of
investigation. Incorporation of blinatumomab in the
first-line treatment setting is in active clinical trials
(NCT02143414, phase II and NCT02003222, phase III).
BiTE antibodies against other antigens (e.g., CD33, CD 79b)
are under active clinical studies for myeloid leukemia and
lymphoma [81, 82]. Since blinatumomab was shown to
activate effector T cells [52, 58], it would be interesting
to study the potential of using blinatumomab for effector
T cell expansion for cancer immunotherapy.
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